ADVERTISEMENT

Add PCSK9 Inhibitor to High-Intensity Statin at Primary PCI, Proposes Sham-Controlled EPIC-STEMI

Steve Stiles   |   Medical News   |   22 September 2022
ADVERTISEMENT

It's best to have patients on aggressive lipid-lowering therapy before discharge after an acute ST-segment elevation myocardial infarction (STEMI), so why not start it right away — even in the cath lab — using some of the most potentLDL-lowering agents available?

That was a main idea behind the randomized, sham-controlled EPIC-STEMI trial, in which...

          

Topic Challenges

left
right